Novartis AG ROA 2006-2018 | NVS

Current and historical return on assets (ROA) values for Novartis AG (NVS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Novartis AG ROA for the three months ending September 30, 2018 was 8.58%.
Novartis AG ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $13.39B $142.99B 9.68%
2018-06-30 $13.85B $142.06B 10.15%
2018-03-31 $8.06B $135.52B 6.00%
2017-12-31 $7.70B $133.08B 5.77%
2017-09-30 $6.68B $134.97B 5.04%
2017-06-30 $6.54B $133.75B 4.94%
2017-03-31 $6.37B $131.99B 4.83%
2016-12-31 $6.71B $130.12B 5.08%
2016-09-30 $6.81B $134.01B 5.14%
2016-06-30 $6.76B $131.44B 5.12%
2016-03-31 $6.79B $132.45B 5.10%
2015-12-31 $17.78B $131.56B 13.30%
2015-09-30 $18.22B $132.93B 13.79%
2015-06-30 $19.56B $135.41B 15.01%
2015-03-31 $20.27B $134.94B 15.86%
2014-12-31 $10.21B $125.39B 8.14%
2014-09-30 $10.75B $125.38B 8.55%
2014-06-30 $9.76B $125.77B 7.78%
2014-03-31 $9.72B $125.33B 7.82%
2013-12-31 $9.18B $126.25B 7.45%
2013-09-30 $9.13B $124.59B 7.44%
2013-06-30 $9.29B $121.07B 7.62%
2013-03-31 $9.42B $121.01B 7.77%
2012-12-31 $9.27B $124.19B 7.67%
2012-09-30 $8.29B $121.22B 6.95%
2012-06-30 $8.36B $118.49B 7.01%
2012-03-31 $8.42B $119.41B 6.95%
2011-12-31 $8.94B $117.50B 7.27%
2011-09-30 $10.11B $121.38B 8.12%
2011-06-30 $9.92B $125.92B 7.92%
2011-03-31 $9.63B $127.22B 8.16%
2010-12-31 $9.79B $123.32B 8.89%
2010-09-30 $9.93B $124.63B 9.62%
2010-06-30 $9.75B $96.92B 10.30%
2010-03-31 $9.37B $95.80B 10.23%
2009-12-31 $8.40B $95.51B 9.64%
2009-09-30 $7.63B $90.69B 9.22%
2009-06-30 $7.63B $84.27B 9.46%
2009-03-31 $7.84B $77.97B 9.75%
2008-12-31 $8.20B $78.30B 10.24%
2008-09-30 $7.56B $82.02B 9.53%
2008-06-30 $12.34B $83.40B 15.81%
2008-03-31 $12.09B $76.32B 16.16%
2007-12-31 $11.95B $75.45B 16.40%
2007-09-30 $12.70B $76.94B 17.89%
2007-06-30 $7.70B $70.62B 11.25%
2007-03-31 $7.40B $68.32B 10.99%
2006-12-31 $7.18B $68.01B 11.05%
2006-09-30 $6.87B $66.86B 11.02%
2006-06-30 $6.66B $65.93B 11.24%
2006-03-31 $6.60B $58.85B 11.76%
2005-12-31 $6.13B $57.73B 11.40%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $202.383B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.009B 18.15
Pfizer (PFE) United States $255.437B 14.40
Merck (MRK) United States $199.761B 17.31
AbbVie (ABBV) United States $132.837B 11.79
Eli Lilly (LLY) United States $116.324B 20.45
Sanofi (SNY) France $113.065B 14.00
Novo Nordisk (NVO) Denmark $108.639B 17.64
AstraZeneca (AZN) United Kingdom $104.862B 13.02
GlaxoSmithKline (GSK) United Kingdom $101.405B 13.63
Bristol-Myers Squibb (BMY) United States $85.837B 14.14